查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
感染疾病體外診斷的全球市場:規模，佔有率，趨勢分析，機會，預測(2019年～2029年):各產品，各技術，各用途，各檢驗場所，各地區
市場調查報告書
商品編碼
1267372

感染疾病體外診斷的全球市場:規模，佔有率，趨勢分析，機會，預測(2019年～2029年):各產品，各技術，各用途，各檢驗場所，各地區

Infectious Disease In Vitro Diagnostics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Technology ; By Application ; By Test Location ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球感染疾病體外診斷的市場規模，2022年是354億1,000萬美金。預計今後，2023年～2029年將以-1.38％的年複合成長率略為減少，2029年成為329億8,000萬美元。

本報告提供全球感染疾病體外診斷市場相關調查，市場概要，以及各產品，各技術，各用途，各檢驗場所，各地區趨勢，競爭情形，及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查架構

第2章 摘要整理

第3章 全球感染疾病體外診斷市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 技術的進步/最近的開發
  • 法律規範
  • 波特的五力分析

第4章 全球感染疾病體外診斷市場概要

  • 市場規模與預測，2019年～2029年
  • 市場佔有率與預測
    • 各產品
      • 設備
      • 試劑
      • 軟體
    • 各技術
      • 免疫測量
      • 分子診斷學
      • 微生物學
      • 其他
    • 各用途
      • MRSA
      • 鏈球菌
      • 難辨梭狀芽孢桿菌
      • VRE
      • CRE
      • 其他
    • 各檢驗場所
      • 照護現場
      • 中央研究所
      • 其他
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第5章 北美的感染疾病體外診斷市場

第6章 歐洲的感染疾病體外診斷市場

第7章 亞太地區的感染疾病體外診斷市場

第8章 南美的感染疾病體外診斷市場

第9章 中東、非洲感染疾病體外診斷市場

第10章 競爭情形

第11章 COVID-19對全球感染疾病體外診斷市場的影響

第12章 企業簡介

  • QIAGEN
  • BD
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc.(Gen-Probe)
  • Abbott
  • Quidel Corp.
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • OraSure Technologies, Inc.
  • 其他

第13章 主要策略性推薦事項

第14章 調查手法

簡介目錄
Product Code: BWC23324

Global Infectious Disease In Vitro Diagnostics Market Size to Reach USD 33 Billion by 2029.

Global infectious disease in vitro diagnostics market is flourishing because of growing geriatric population susceptible to infectious diseases and surging demand for POC testing owing to the pandemic.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global infectious disease in vitro diagnostics market size at USD 35.41 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave anticipates global infectious disease in vitro diagnostics market size to slightly decline at a CAGR of -1.38% reaching a value of USD 32.98 billion by 2029. Major growth drivers for global infectious disease in vitro diagnostics market include increasing number of elderly individuals who are vulnerable to contagious illnesses, the COVID-19 pandemic's high requirement for point-of-care (PoC) testing, greater recognition of the importance of early detection, and the growing occurrence of infectious diseases. The pandemic led to a significant shift in the market, as innovative products for testing SARS-CoV-2 were launched, resulting in substantial growth in the industry in 2020 and 2021. The increasing adoption of these products played a crucial role in the growth of the market. As a result of the rapid installation of PCR instruments, there has been an opportunity to utilize PCR tests for other infectious diseases, such as influenza, due to the declining need for SARS-CoV-2 tests in 2022. The growing geriatric population is expected to be one of the growth drivers of this market, given that aging is the leading risk factor for the development of diseases such as cardiovascular and neurological diseases. However, high cost associated with testing is anticipated to hinder the growth of global infectious disease in vitro diagnostics market during the period in analysis.

Global Infectious Disease In Vitro Diagnostics Market - Overview:

The infectious disease in vitro diagnostics (IVD) market refers to the use of diagnostic tests and devices to detect and diagnose infectious diseases in biological samples such as blood, urine, and other bodily fluids. These tests are performed in vitro, meaning outside of the body in a laboratory setting. The IVD market for infectious diseases includes a range of tests such as immunoassays, molecular diagnostics, and microbiology culture tests, among others. These tests aid in the identification of infectious agents such as bacteria, viruses, fungi, and parasites, and help in the management and treatment of infectious diseases.

Impact of COVID-19 on Global Infectious Disease In Vitro Diagnostics Market

COVID-19 had a positive impact on the infectious disease in vitro diagnostics market. The increased need for detecting cases during the pandemic resulted in higher utilization rates of IVD devices. Regulatory authorities also made testing mandatory to contain the spread of the disease, further driving up demand for IVD devices. However, with the decrease in COVID-19 cases, there may be a decrease in demand for diagnostics. Nonetheless, the infectious disease in vitro diagnostics market is expected to continue growing due to the emergence of new diseases. More people are becoming health-conscious and monitoring their health regularly, which is also contributing to the rise in demand for IVD devices.

Global Infectious Disease In Vitro Diagnostics Market - By Application:

Based on application, global infectious disease in vitro diagnostics market is segmented into MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, and others (Respiratory Virus, Candida, TB And Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, and COVID-19). The COVID-19 application segment was the most dominant segment in the global industry. This can be attributed to the increased utilization of SARS-CoV-2 testing to curb the spread of the virus. Additionally, government initiatives to improve public testing and the launch of innovative products have been significant factors driving the growth of this sector. The TB and HIV segments have also experienced rapid growth due to improved testing methods. Furthermore, the respiratory virus segment's influenza testing has accelerated with the introduction of new diagnostic tests that allow differentiation between SARS-CoV-2 and influenza, facilitating prompt treatment. Tuberculosis, caused by Mycobacterium tuberculosis, is a contagious infection that remains a global epidemic. The WHO reported 130 new cases per 100,000 annually in 2020, but there has been a decline in the incidence rate in recent years, with a 9% drop between 2015 and 2019.

Competitive Landscape:

Major players operating in global infectious disease in vitro diagnostics market include: QIAGEN, BD, bioMerieux SA, F. Hoffmann-La Roche, Ltd., Hologic, Inc. (Gen-Probe), Abbott, Quidel Corp., Siemens Healthineers AG, Bio-Rad Laboratories, Inc., Danaher Corp., and OraSure Technologies, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Infectious Disease In Vitro Diagnostics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Infectious Disease In Vitro Diagnostics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Infectious Disease In Vitro Diagnostics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Growing Geriatric Population Susceptible to Infectious Diseases
      • 3.2.1.2. High Demand for POC Testing Owing to the Pandemic
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost Associated with Testing
    • 3.2.3. Opportunities
      • 3.2.3.1. Rising Prevalence of Infectious Diseases.
    • 3.2.4. Challenges
      • 3.2.4.1. Lack of Accurate result of Testing
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Infectious Disease In Vitro Diagnostics Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Instruments
      • 4.2.1.2. Reagents
      • 4.2.1.3. Software
    • 4.2.2. By Technology
      • 4.2.2.1. Immunoassay
      • 4.2.2.2. Molecular Diagnostics
      • 4.2.2.3. Microbiology
      • 4.2.2.4. Others
    • 4.2.3. By Application
      • 4.2.3.1. MRSA
      • 4.2.3.2. Streptococcus
      • 4.2.3.3. Clostridium Difficile
      • 4.2.3.4. VRE
      • 4.2.3.5. CRE
      • 4.2.3.6. Others (Respiratory Virus, Candida, TB And Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19)
    • 4.2.4. By Test Location
      • 4.2.4.1. Point of Care
      • 4.2.4.2. Central Laboratories
      • 4.2.4.3. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Infectious Disease In vitro Diagnostics Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Technology
    • 5.2.3. By Application
    • 5.2.4. By Test Location
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Product
      • 5.2.5.1.2. By Technology
      • 5.2.5.1.3. By Application
      • 5.2.5.1.4. By Test Location
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Product
      • 5.2.5.2.2. By Technology
      • 5.2.5.2.3. By Application
      • 5.2.5.2.4. By Test Location

6. Europe Infectious Disease In vitro Diagnostics Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By Test Location
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Product
      • 6.2.5.1.2. By Technology
      • 6.2.5.1.3. By Application
      • 6.2.5.1.4. By Test Location
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Product
      • 6.2.5.2.2. By Technology
      • 6.2.5.2.3. By Application
      • 6.2.5.2.4. By Test Location
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Product
      • 6.2.5.3.2. By Technology
      • 6.2.5.3.3. By Application
      • 6.2.5.3.4. By Test Location
      • 6.2.5.4. France
      • 6.2.5.4.1. By Product
      • 6.2.5.4.2. By Technology
      • 6.2.5.4.3. By Application
      • 6.2.5.4.4. By Test Location
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Product
      • 6.2.5.5.2. By Technology
      • 6.2.5.5.3. By Application
      • 6.2.5.5.4. By Test Location
      • 6.2.5.6. Belgium
      • 6.2.5.6.1. By Product
      • 6.2.5.6.2. By Technology
      • 6.2.5.6.3. By Application
      • 6.2.5.6.4. By Test Location
      • 6.2.5.7. Russia
      • 6.2.5.7.1. By Product
      • 6.2.5.7.2. By Technology
      • 6.2.5.7.3. By Application
      • 6.2.5.7.4. By Test Location
      • 6.2.5.8. The Netherlands
      • 6.2.5.8.1. By Product
      • 6.2.5.8.2. By Technology
      • 6.2.5.8.3. By Application
      • 6.2.5.8.4. By Test Location
      • 6.2.5.9. Rest of Europe
      • 6.2.5.9.1. By Product
      • 6.2.5.9.2. By Technology
      • 6.2.5.9.3. By Application
      • 6.2.5.9.4. By Test Location

7. Asia-Pacific Infectious Disease In vitro Diagnostics Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By Test Location
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Product
      • 7.2.5.1.2. By Technology
      • 7.2.5.1.3. By Application
      • 7.2.5.1.4. By Test Location
      • 7.2.5.2. India
      • 7.2.5.2.1. By Product
      • 7.2.5.2.2. By Technology
      • 7.2.5.2.3. By Application
      • 7.2.5.2.4. By Test Location
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Product
      • 7.2.5.3.2. By Technology
      • 7.2.5.3.3. By Application
      • 7.2.5.3.4. By Test Location
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Product
      • 7.2.5.4.2. By Technology
      • 7.2.5.4.3. By Application
      • 7.2.5.4.4. By Test Location
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Product
      • 7.2.5.5.2. By Technology
      • 7.2.5.5.3. By Application
      • 7.2.5.5.4. By Test Location
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Product
      • 7.2.5.6.2. By Technology
      • 7.2.5.6.3. By Application
      • 7.2.5.6.4. By Test Location
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Product
      • 7.2.5.7.2. By Technology
      • 7.2.5.7.3. By Application
      • 7.2.5.7.4. By Test Location
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Product
      • 7.2.5.8.2. By Technology
      • 7.2.5.8.3. By Application
      • 7.2.5.8.4. By Test Location
      • 7.2.5.9. Vietnam
      • 7.2.5.9.1. By Product
      • 7.2.5.9.2. By Technology
      • 7.2.5.9.3. By Application
      • 7.2.5.9.4. By Test Location
      • 7.2.5.10. Rest of APAC
      • 7.2.5.10.1. By Product
      • 7.2.5.10.2. By Technology
      • 7.2.5.10.3. By Application
      • 7.2.5.10.4. By Test Location

8. Latin America Infectious Disease In vitro Diagnostics Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Test Location
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Product
      • 8.2.5.1.2. By Technology
      • 8.2.5.1.3. By Application
      • 8.2.5.1.4. By Test Location
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Product
      • 8.2.5.2.2. By Technology
      • 8.2.5.2.3. By Application
      • 8.2.5.2.4. By Test Location
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Product
      • 8.2.5.3.2. By Technology
      • 8.2.5.3.3. By Application
      • 8.2.5.3.4. By Test Location
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Product
      • 8.2.5.4.2. By Technology
      • 8.2.5.4.3. By Application
      • 8.2.5.4.4. By Test Location
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Product
      • 8.2.5.5.2. By Technology
      • 8.2.5.5.3. By Application
      • 8.2.5.5.4. By Test Location

9. Middle East & Africa Infectious Disease In vitro Diagnostics Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By Test Location
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Product
      • 9.2.5.1.2. By Technology
      • 9.2.5.1.3. By Application
      • 9.2.5.1.4. By Test Location
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Product
      • 9.2.5.2.2. By Technology
      • 9.2.5.2.3. By Application
      • 9.2.5.2.4. By Test Location
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Product
      • 9.2.5.3.2. By Technology
      • 9.2.5.3.3. By Application
      • 9.2.5.3.4. By Test Location
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Product
      • 9.2.5.4.2. By Technology
      • 9.2.5.4.3. By Application
      • 9.2.5.4.4. By Test Location
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Product
      • 9.2.5.5.2. By Technology
      • 9.2.5.5.3. By Application
      • 9.2.5.5.4. By Test Location
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Product
      • 9.2.5.6.2. By Technology
      • 9.2.5.6.3. By Application
      • 9.2.5.6.4. By Test Location
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Product
      • 9.2.5.7.2. By Technology
      • 9.2.5.7.3. By Application
      • 9.2.5.7.4. By Test Location
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Product
      • 9.2.5.8.2. By Technology
      • 9.2.5.8.3. By Application
      • 9.2.5.8.4. By Test Location

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Infectious Disease In Vitro Diagnostics Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Infectious Disease In Vitro Diagnostics Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. QIAGEN
  • 12.2. BD
  • 12.3. bioMerieux SA
  • 12.4. F. Hoffmann-La Roche, Ltd.
  • 12.5. Hologic, Inc. (Gen-Probe)
  • 12.6. Abbott
  • 12.7. Quidel Corp.
  • 12.8. Siemens Healthineers AG
  • 12.9. Bio-Rad Laboratories, Inc.
  • 12.10. Danaher Corp.
  • 12.11. OraSure Technologies, Inc.
  • 12.12. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations